https://www.globaldata.com/newsletter/details/novartis-bags-paediatric-fda-label-expansion-for-lutathera_302438/?newsletterdate=2024-04-25&hubspotcategory=gd-pharma-prospects-daily&utm_source=website&utm_medium=top_navigation&utm_content=other_daily_news_articles&utm_campaign=type2_pharma
@Phaedrus
An example of label expansion by from our buddies at Novartis
Question- we have run adult trials with a less potent product- could that data along with EAP real world evidence contribute to an expansion into adults?
Reg
ASX Hot too!, page-298
-
- There are more pages in this discussion • 374 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |